MDMA-Assisted Therapy vs Somatic Experiencing

MDMA-Assisted Therapy

Tradition

Psychedelic

Founder

MAPS / Mithoefer (2021)

Review status

4 source checks available

Official sources

Guidelines and official sources (4)

3 clinical guideline checks · 1 regulatory source check

Read the recommendation and its scope. A source may discuss an approach without recommending it.

• NDA 215455: midomafetamine complete response letter

  US Food and Drug Administration · 2024-08-08; Reference ID 5427030 · Regulatory source · Complete response issues 1–3, pages 1–4; additional comments pages 5–6

  Not a treatment recommendation

  The letter verifies the 2024 nonapproval decision and identifies safety reporting, durability and bias concerns. Psychotherapy-contribution questions appear separately as additional comments.

  Scope: Midomafetamine application NDA 215455 for PTSD

  Source checked 2026-09-06

• Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder

  VA/DoD · 2023 · Clinical guideline · Recommendation 23; Table 6, p.37

  Insufficient evidence for or against

  VA/DoD finds insufficient evidence for or against MDMA-assisted psychotherapy. The guideline’s evidence cutoff precedes later trials and regulatory decisions.

  Scope: MDMA-assisted psychotherapy for adults with PTSD; evidence reviewed through May 2022.

  Source checked 2026-09-06

• Management of Major Depressive Disorder

  VA/DoD · Version 4.0, February 2022; evidence through January 2021 · Clinical guideline · Recommendation 35; pp.26,67–68

  Recommendation against the stated use

  VA/DoD strongly recommends against MDMA for MDD outside research. This 2022 guideline used evidence through January 2021; it does not assess later trials or every diagnosis.

  Scope: MDMA for MDD outside research settings.

  Source checked 2026-09-06

• Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults

  American Psychological Association · Approved February 2025; 2025 update · Clinical guideline · Psychedelic interventions, printed p.14 (PDF p.18)

  Insufficient evidence for or against

  APA finds insufficient evidence for or against this intervention in the reviewed comparisons.

  Scope: Adults with PTSD; MDMA-assisted psychotherapy versus the inactive or low-dose active comparators reviewed.

  Source checked 2026-09-06

Focus

Experiential + Processing

Format

Individual (co-therapist)

Duration

Short (3 sessions)

Somatic Experiencing

Tradition

Somatic

Founder

Peter Levine (1997)

Review status

1 condition assessment available

Official sources

Guidelines and official sources (2)

2 clinical guideline checks

Read the recommendation and its scope. A source may discuss an approach without recommending it.

• Clinical Practice Guideline for Management of PTSD and Acute Stress Disorder

  VA/DoD · 2023 · Clinical guideline · Recommendation 27

  Insufficient evidence for or against

  VA/DoD finds insufficient evidence for or against somatic experiencing for PTSD.

  Scope: Adults with PTSD

  Source checked 2026-09-06

• Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder in Adults

  American Psychological Association · Approved February 2025; 2025 update · Clinical guideline · Complementary and integrative interventions, printed page 13 (PDF page 17)

  Insufficient evidence for or against

  APA finds insufficient evidence to recommend for or against somatic experiencing for adult PTSD.

  Scope: Somatic experiencing for adults with PTSD

  Source checked 2026-09-06

Focus

Somatic + Experiential

Format

Individual

Duration

Medium-term

Condition-specific assessments

Each conclusion applies to the population and use described. These source-based assessments do not certify the full entry or replace expert clinical review.

PTSD & Acute Trauma

Population and scope: Adults with PTSD.

Guideline evidence inconclusive

VA/DoD 2023 recommendation 27 finds evidence insufficient for or against Somatic Experiencing.

Source assessment dated 2026-09-08

• VA/DoD (2023): PTSD and acute stress disorder clinical practice guideline

MDMA-Assisted Therapy

Core mechanism: MDMA reduces the fear response and increases trust and empathy, making it possible to stay with trauma material inside the therapeutic relationship

Ontology: PTSD maintained by overwhelming fear that prevents therapeutic engagement; MDMA lowers this barrier pharmacologically

Somatic Experiencing

Core mechanism: Alternating in small doses between activation and a settled resource state ('pendulation') is held to complete defensive responses that were interrupted at the time of the threat and remain bound in the body

Ontology: Incomplete defensive responses (fight/flight/freeze) remain bound in the nervous system as undischarged survival energy

Linked only in the Somatic Experiencing entry

MDMA-Assisted Therapy

Philosophical roots: Mithoefer (inner healing intelligence); Rogers (organismic wisdom, given conditions); Buber (I-Thou enabled pharmacologically); trauma processing theory

Blind spots: FDA declined approval (2024); methodological concerns about unblinding; not currently legally available outside research

Therapeutic voice: You're safe here. If something difficult comes up, you can move toward it. You don't have to do this alone.

Somatic Experiencing

Philosophical roots: Reich/Lowen (body holds defense; Levine worked in this lineage but did not study with Reich, who died in 1957); Merleau-Ponty (lived body); Darwin (survival instincts); ethology (Tinbergen, Lorenz: animal defensive responses); James-Lange (emotion as bodily process)

Blind spots: Risk of over-physiologizing psychological meaning; limited manualization makes research difficult; can be vague in application

Therapeutic voice: Let's leave that where it is for a moment and come back to your feet on the floor. When you're ready we'll go back and take a smaller piece of it.